ASCO GU Symposium Announces New Findings on Tumor Reduction and Survival Outcomes in Advanced Renal Cell Carcinoma
The latest analysis, presented Feb. 13-14 at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib (Lenvima) and pembrolizumab (Keytruda) combination in treating this aggressive form of kidney cancer. Hutson played a key role in the study and provided insights into the impact of these findings.
“This analysis reinforces that greater tumor shrinkage correlates with improved survival outcomes,” Hutson said. “We now have compelling evidence that reducing overall tumor burden not only extends survival but also enhances the effectiveness of subsequent treatments, setting patients up for better long-term prognoses.”
The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies. The new findings demonstrate that patients with greater reductions in total tumor size at disease progression had significantly longer median survival rates. Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve their IMDC risk scores, further supporting the regimen’s impact on long-term survival.
“These findings emphasize the importance of aggressive tumor reduction in the fight against renal cell carcinoma,” Hutson added. “The data suggest that this combination therapy offers the best outcomes among currently available treatments, making it a strong contender for first-line treatment in advanced renal cell carcinoma.”
TTUHSC and UMC Health System remain committed to advancing cancer treatment and improving patient outcomes through innovative research and clinical excellence.
About Texas Tech University Health Sciences Center
TTUHSC is a medical education, research and patient care leader dedicated to improving health outcomes across Texas and beyond.
About UMC Health System
UMC Health System is a nationally recognized academic medical center committed to delivering advanced patient care, innovative research and comprehensive cancer treatment.
Related Stories
TTUHSC Researchers Seek Novel Therapies for Chronic Pain
The National Institute of Neurological Disorders and Stroke at the NIH recently awarded a $1.94 million grant to Mahmoud Salama Ahmed, Ph.D., and his project team from the Department of Pharmaceutical Sciences at TTUHSC. Jerry H. Hodge School of Pharmacy.
TTUHSC and TTUHSC El Paso Named to National Academy of Inventors Top 100
For the third consecutive year in a row, the National Academy of Inventors (NAI) ranked the Texas Tech University System (TTU System) among the Top 100 U.S. Universities Granted Utility Patents for 2024. The TTU System, which includes Texas Tech University Health Sciences Center (TTUHSC) and TTUHSC El Paso, ranked 75th.
TTUHSC Recognizes Student Research During Amarillo Research Symposium
More than 100 student and trainee researchers from the Texas Tech University Health Sciences Center (TTUHSC) presented research findings at the 2025 Student Research Day on April 11.
Recent Stories
Measles Outbreak: What to Know From The Future of Health
Kelissa Huse, an assistant professor and laboratory manager in the Molecular Pathology Program at TTUHSC, spoke about measles, the outbreak and what West Texans needs to know about the disease.
Santos Named Department of Surgery Chair for TTUHSC School of Medicine in Lubbock
As the new Department of Surgery chair for the School of Medicine in Lubbock, Ariel Santos, M.D., M.P.H., seeks to elevate TTUHSC’s role as the Hub of Surgery for West Texas.
Covenant Health Brings Kidney Transplant Surgery Back to West Texas
The Kidney Transplant Program at Covenant Medical Center will provide life-changing opportunities for patients suffering from end-stage renal disease (ESRD) and chronic kidney conditions.